Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') Disclosure Relating To Receipt Of Demand-Cum-Show Cause Notice Received From Office Of The Principal Commissioner Of Customs

 In terms of Regulation 30 and Schedule III of SEBI (LODR) Reg. 2015 read with SEBI Circular dated July 13, 2023, please find attached herewith the disclosure relating to receipt of Demand cum show cause notice received from office of the Principal Commissioner of Customs.
16-12-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 Pursuant to SEBI (Listing Obligations and Disclosure Requirements (Regulations), 2015, as amended, we are pleased to inform you that the Nomination and Remuneration Committee has issued and allotted 89,794 Equity Shares of Rs. 5/- Each under JPL ESOP 2022, to the eligible employees of the Company, upon exercise of vested options. These Shares shall rank pari passu with the existing shares of the Company, in all respects.
04-12-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on November 04, 2023, in ''Business Standard'' (English) and Business Standard (''Hindi'') newspaper providing extracts of Unaudited Financial Results for the quarter and half year ended September 30, 2023.
04-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Related Party Transactions For The Half Year Ended From April 01, 2023 To September 30, 2023

 Pursuant to Regulation 23(9) of SEBI Listing Regulations, please find enclosed herewith disclosure of related party transactions for the half year ended commencing from April 01, 2023 to September 30, 2023
03-11-2023
Bigul

Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Jagsonpal Pharmaceuticals Ltd.

 Jagsonpal Pharmaceuticals announced Q2FY24 & H1FY24 results: Q2FY24: Revenues: Rs 57.8 crore, showing a decrease of 4.5% compared to Q2FY23. Operating EBITDA: Rs 12.6 crore. EBITDA Margin: 21.7%, an increase of 100 basis points (bps) from Q2FY23. ESOP Cost: Rs 4.2 crore. PAT (Profit After Tax): Rs 7.5 crore, marking a decrease of 27.9% compared to Q2FY23. H1FY24: Revenues: Rs 118.0 crore, showing a decrease of 2.6% compared to H1FY23. Operating EBITDA: Rs 25.4 crore, reflecting a 17.6% increase from H1FY23. EBITDA Margin: 21.5%, an increase of 360 bps from H1FY23. ESOP Cost: Rs 8.4 crore. PAT (Profit After Tax): Rs 15.0 crore, reflecting a 12.8% increase compared to H1FY23. Commenting on the Company’s performance, Manish Gupta, Managing Director stated, “We had a satisfactory outcome for the period, as the performance should be seen in the context of challenging external operating environment with slowing industry coupled with internal challenges in our flagship products - hyper-competition with 75+ competitors in Divatrone®(Dydrogesterone) and availability of counterfeits products in Indocap SR® (Indomethacin). Overall, we maintained our profitability for the quarter, with 100 bps improvement in operating margins, even as we reported a 4.5% decline in revenues. We maintained cash balance at Rs 125 crore despite dividend payout of Rs 13.1 crore during the quarter. We introduced certain structural initiatives including strengthening anti-counterfeit packing for our key brands. These, along with proposed new product launches gives us the confidence of returning to top-line growth from Q4FY24 onwards.” Result PDF
03-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please enclosed herewith Press release and earning presentation for the quarter and half year ended September 30, 2023.
03-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On November 3, 2023 - Proposed Divestment Of Company'S Faridabad Facility

 Board of Director at its meeting held today, inter alia considered and approved in principle divestment of Company''s Faridabad facility.
03-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Outcome Of Board Meeting Held On November 03, 2023 Along With Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2023

 Please enclose herewith quarterly and half yearly financial results with limited review report for the quarter and half year ended on September 30, 2023.
03-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 03, 2023 Along With Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2023

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2023. The Board Meeting commenced at 12:45 p.m. and concluded at 13:40 p.m.
03-11-2023
Bigul

JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of Press Release issued by the Company titled "Promoting Women''s Health and Hygiene: Building Sanitation Facilities at Girls Schools in Uttarakhand and Punjab".
31-10-2023
Next Page
Close

Let's Open Free Demat Account